Plus   Neg

INOVIO To Develop DMAb Candidates To Treat COVID-19 With DARPA Funding - Quick Facts

Biotechnology company INOVIO (INO) said Tuesday it will develop DNA-encoded monoclonal antibody or dMAb candidates to treat COVID-19 with funding from the U.S. Defense Advanced Research Projects Agency or DARPA, and the Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense or JPEO-CBRND.

InOVIO said that the company and a team of scientists from the Wistar Institute, AstraZeneca, the University of Pennsylvania, and Indiana University received a $37.6 million grant to use INOVIO's DNA-encoded monoclonal antibody or dMAb technology to develop anti-SARS-CoV-2-specific dMAbs.

The company noted that the dMAbs could offer versatile capabilities to function as both a therapeutic and preventive treatment for COVID-19.

As part of DARPA's two-year grant, INOVIO and Wistar teams will construct COVID-19 dMAb candidates mirroring AstraZeneca's traditional recombinant monoclonal antibody candidates currently being tested in clinical trials to treat COVID-19.

INOVIO noted that dMAb candidates can be quickly developed and produced in vivo, offering a cost-effective as well as scalable therapeutic and preventive option for treatment of SARS-CoV-2 virus infection.

The dMAb candidates will then be advanced into preclinical studies and then into rigorous, first-in-human clinical trials within one year of funding.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Brazos Electric Power Cooperative Inc., the largest power generation and transmission cooperative in Texas, filed for Chapter 11 bankruptcy protection citing a huge bill from the state's grid operator following major outages recently amid the winter storm. Brazos received a $1.8 billion bill from electricity grid operator Electric Reliability Council of Texas or ERCOT. El Abuelito Cheese is recalling certain types of cheese and cheese products for fear of potential contamination with Listeria Monocytogenes, a deadly bacteria, the U.S. Food & Drug Administration said in a statement. The recall involves Queso Fresco (Fresh, soft cheese), Quesillo (Oaxaca, string cheese), and Requeson (Ricotta) products. Technology company CAE Inc. (CAE.TO, CAE) agreed Monday to acquire the military training division of aerospace and defense technology firm L3Harris Technologies Inc. (LHX) for $1.05 billion, subject to customary adjustments. The acquisition will expand CAE's position as a platform-agnostic training...
Follow RTT